Medco, which operates a major pharmacy and distribution center in Whitestown, got a boost from higher prices on brand-name
drugs and from greater sales of more profitable generic drugs.
Purdue University’s decision to close the Chao Center in West Lafayette is a setback for Indiana’s effort to grow
a vibrant contract drug manufacturing sector. But it’s just the latest in a series of unexpected changes—not all for
the worse—since Indianapolis-based BioCrossroads launched a contract drug manufacturing initiative in late 2007.
The Purdue Research Foundation says the Chao Center for Industrial Pharmacy and Contract Manufacturing was unable to become
self-sustaining in part because of the recession.
The Indianapolis-based provider of clinical research animals has promoted senior manager Hans Thunem to its top spot.
Drug prices rose faster last year than they have in a decade—just in time for big rebates the drug industry promised
as part of the health reform law.
Eli Lilly and Co. will repurchase rights to develop and market antidepressant Cymbalta outside the U.S. and Japan from European
partner Boehringer Ingelheim for an initial payment of $400 million.
Once-weekly form of Byetta is awaiting the FDA’s OK. Analyst predict the new version of the drug, if approved, could rack
up sales of $2 billion annually.
Louisiana was one of 13 states that filed individual suits in state courts over allegations that Lilly pushed Zyprexa for
uses that had not been approved by federal regulators.
Eli Lilly and Co. won a U.S. court ruling Wednesday that bars Teva Pharmaceutical Industries Ltd. from selling a generic version
of the cancer drug Gemzar until November.
Eli Lilly and Co.’s Alimta has received the preliminary backing of a United Kingdom agency as a maintenance treatment for
patients with the most common form of lung cancer.
Deal with unit of Massachusetts-based Thermo Fisher Scientific would keep many of the employees working in same
location.
Indianapolis-based Eli Lilly and Co. sued rival drugmaker Hospira Inc. to prevent it from selling a generic version of the
cancer drug Gemzar before a patent on the medicine expires in 2013.
Monday’s decision throws out a $65.2 million patent-infringement verdict won by Ariad for royalties on Lilly’s osteoporosis
drug Evista and sepsis medicine Xigris.
Sweeping changes phase in slowly for most, but insurers, hospitals, drug companies, employers, workers, medical device makers
and more will eventually feel impact.
Drugmakers and insurers could gain millions of customers under the legislation, but the industry also will pay new fees and
face stricter rules that may shrink profit and fuel mergers.
Netherlands-based Synthon Pharmaceuticals is seeking U.S. Food and Drug Administration approval to sell a copy of the medicine.
Pharmaceuticals stolen Sunday morning could be worth up to $75 million.
Eli Lilly & Co., the maker of the impotence pill Cialis, bought exclusive rights from Australia’s Acrux Ltd. to
an underarm testosterone lotion called Axiron for men with limited sex drive due to low levels of the hormone.
Indianapolis-based Lilly will pay Acrux of West Melbourne, Australia, a $50 million license fee, plus $3 million when manufacturing
assets are transferred, but the deal could be worth millions more.
Regulators won’t require more time-consuming tests of the drug, but want Eli Lilly and Co. and its partners to clarify labeling,
manufacturing
processes.
